iifl-logo

Pfizer Ltd AGM

5,227
(1.15%)
Sep 12, 2025|12:00:00 AM

Pfizer CORPORATE ACTIONS

14/09/2024calendar-icon
14/09/2025calendar-icon
PurposeAGM DateAnnouncement Date
AGM21 Jul 202519 May 2025
Convening of the 74th Annual General Meeting of the Company on Monday, July 21, 2025, through Video-Conferencing (VC) / Other Audio Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. Pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we submit herewith notice of the 74th Annual General Meeting scheduled on Monday, July 21, 2025. (As per BSE Announcement Dated on 29/06/2025) Please find enclosed proceedings of the 74th Annual General Meeting of the Company held on Monday, July 21, 2025 at 3.00 P.M. IST. (As Per BSE Announcement Dated on: 21/07/2025) Pursuant to Regulation 44 of SEBI (LODR) Regulations, 2015, we submit herewith the consolidated scrutinizers report of the votes cast during electronic voting and electronic polling process conducted during the 74th Annual General Meeting of the Company held on Monday, July 21, 2025 at 3.00 P.M. IST. (As per BSE Announcement Dated on 22/07/2025)

Pfizer: Related News

Pfizer India Q1 Profit Rises 27%; Unveils PCV20 Vaccine

Revenue also saw healthy growth. It was up 7.1% to ₹604 crore from ₹563 crore a year earlier.

14 Aug 2025|02:27 PM
Read More
Pfizer Partners with Mylan to Boost Ativan and Pacitane Sales in India

Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.

23 Feb 2025|11:51 PM
Read More
Pfizer Ties Up with Mylan to Boost Ativan and Pacitane Sales in India

The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.

21 Feb 2025|05:31 PM
Read More
Pfizer India Q3 Profit Slips 2% YoY

Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24

31 Jan 2025|11:34 PM
Read More
Pfizer reports 61% YoY profit surge in Q1 2024

At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.

30 Jul 2024|09:44 AM
Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.